Expert Opinion on Drug Discovery

Scope & Guideline

Connecting Experts in Drug Development

Introduction

Explore the comprehensive scope of Expert Opinion on Drug Discovery through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Expert Opinion on Drug Discovery in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1746-0441
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationEXPERT OPIN DRUG DIS / Expert. Opin. Drug Discov.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Expert Opinion on Drug Discovery' focuses on providing insights and reviews related to the methodologies and advancements in drug discovery and development. It aims to address various challenges in the field and explore new frontiers that can lead to innovative therapeutic solutions.
  1. Innovative Drug Discovery Strategies:
    The journal emphasizes novel approaches in drug discovery, including the use of artificial intelligence, machine learning, and computational methods to enhance the efficiency and accuracy of drug design.
  2. Targeted Therapeutics Development:
    It covers research aimed at developing drugs targeting specific diseases, particularly in oncology, neurology, and infectious diseases, highlighting the importance of understanding disease mechanisms.
  3. Repurposing Existing Drugs:
    The journal explores strategies for repurposing existing drugs for new therapeutic uses, especially in the context of emerging health crises such as COVID-19.
  4. Translational Research:
    There is a strong focus on bridging the gap between preclinical studies and clinical applications, emphasizing the relevance of animal models and in vitro systems in drug discovery.
  5. Emerging Technologies in Drug Discovery:
    The journal discusses advancements in technologies such as high-throughput screening, nanotechnology, and 3D cell culture models, which are pivotal for modern drug discovery.
  6. Challenges in Drug Development:
    It addresses the various challenges faced in drug development, including issues of bioavailability, drug resistance, and regulatory hurdles.
The journal has seen a significant increase in interest in several emerging themes that reflect the forefront of drug discovery research. These trends indicate a shift towards more integrated and technology-driven approaches.
  1. Artificial Intelligence and Machine Learning:
    There is a growing emphasis on the application of AI and machine learning in drug discovery, focusing on their potential to accelerate the identification and optimization of drug candidates.
  2. Complex Disease Models:
    Research on complex disease models, including polygenic and multifactorial diseases, is trending as scientists seek to better mimic human disease in preclinical settings.
  3. Biologics and RNA-based Therapeutics:
    The exploration of biologics, including monoclonal antibodies and RNA-targeted therapies, has gained traction as a promising area for innovative drug development.
  4. Personalized Medicine Approaches:
    There is an emerging focus on personalized medicine, tailoring drug discovery and development processes to individual patient profiles and genetic backgrounds.
  5. Sustainable and Ethical Drug Discovery:
    Research addressing the ethical implications and sustainability of drug discovery processes, including the use of natural products and environmentally friendly methodologies, is increasingly prominent.

Declining or Waning

While 'Expert Opinion on Drug Discovery' continues to evolve, certain themes have become less prominent in recent publications, reflecting shifts in research focus and emerging methodologies.
  1. Traditional Drug Discovery Techniques:
    There has been a noticeable decline in papers focusing solely on traditional drug discovery methods, as the field increasingly adopts advanced technologies and computational approaches.
  2. General Discussions on Drug Discovery:
    Papers that provide general overviews without a specific focus on innovative methodologies or case studies are becoming less frequent, as the journal seeks to present more targeted and impactful research.
  3. Single Target Drug Discovery:
    The trend towards polypharmacology and multi-target strategies indicates a waning interest in developing drugs that target single pathways or receptors, reflecting a more complex understanding of disease mechanisms.

Similar Journals

SLAS Discovery

Exploring New Horizons in Molecular Medicine
Publisher: ELSEVIER SCIENCE INCISSN: 2472-5552Frequency: 10 issues/year

SLAS Discovery is a leading academic journal published by Elsevier Science Inc. that serves as a pivotal resource in the fields of Analytical Chemistry, Biochemistry, Biotechnology, and Molecular Medicine. Since its inception in 2017, the journal has become increasingly influential, attaining a Q1 ranking in Analytical Chemistry and notable Q2 rankings in the associated fields as of 2023. With an impressive Scopus rank that places it within the top percentile of its categories, SLAS Discovery highlights groundbreaking research and methodologies impacting drug discovery and development. The journal advocates for open access, ensuring that its curated content is widely available to the scientific community, fostering collaboration and innovation. Researchers, professionals, and students alike will find value in the journal's comprehensive reviews and original research articles that contribute to the advancement of scientific knowledge and applications in life sciences.

Drug Discoveries and Therapeutics

Unveiling the future of drug development and therapy.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

CURRENT PHARMACEUTICAL DESIGN

Unveiling the Future of Drug Discovery and Design
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Pharmaceutical Patent Analyst

Navigating the Nexus of Innovation and Intellectual Property
Publisher: TAYLOR & FRANCIS LTDISSN: 2046-8954Frequency: 6 issues/year

Pharmaceutical Patent Analyst, published by Taylor & Francis Ltd, is a premier journal dedicated to the evolving fields of pharmaceutical science and patent law. Established in 2012, this journal provides a rigorous platform for scholarly articles, analytical studies, and insightful reviews that delve into the intersection of drug discovery, pharmaceutical innovation, and intellectual property rights. With a Q2 category ranking in Pharmaceutical Science and Q3 rankings in both Drug Discovery and Medicine (miscellaneous), it is recognized for its impactful contributions to the academic community and industry professionals alike. The journal aims to enhance the understanding of patent strategies, explore emerging pharmaceutical technologies, and foster dialogue on regulatory challenges, ultimately facilitating innovation in drug development. Although it does not currently offer open access, its comprehensive and high-quality content remains essential for researchers, professionals, and students pursuing excellence in pharmaceutical research and patent analysis.

International Journal for Parasitology-Drugs and Drug Resistance

Exploring Therapeutic Frontiers in Parasitology
Publisher: ELSEVIER SCI LTDISSN: 2211-3207Frequency: 3 issues/year

International Journal for Parasitology-Drugs and Drug Resistance, published by ELSEVIER SCI LTD, is a premier open access journal that has been at the forefront of parasitology research since its inception in 2011. With an impressive impact factor and recognition as a Q1 journal in multiple categories including Infectious Diseases, Parasitology, and Pharmacology, it serves as an essential resource for researchers, professionals, and students looking to advance their understanding of drug resistance and therapeutic strategies against parasitic infections. Based in the Netherlands, the journal’s scope encompasses a wide range of topics dedicated to innovative drug development, resistance mechanisms, and treatment efficacy, empowering the scientific community with high-quality, peer-reviewed articles. Engaging with this publication not only enhances the discourse on parasitological challenges but also contributes to the global fight against infectious diseases. With the adoption of open access since 2011, the journal ensures that valuable insights and knowledge remain readily accessible to all stakeholders in the field.

ACS Pharmacology & Translational Science

Advancing the frontiers of pharmacological research.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.

Pharmaceuticals

Advancing Pharmaceutical Science for a Healthier Tomorrow
Publisher: MDPIISSN: Frequency: 12 issues/year

Ph pharmaceuticals is a leading peer-reviewed journal published by MDPI, focused on the dynamic fields of pharmaceutical science, drug discovery, and molecular medicine. Since its inception, the journal has established itself as a vital resource for researchers and practitioners, boasting an impressive impact factor reflected in its Q1 and Q2 quartile rankings across multiple categories, including Pharmaceutical Science and Drug Discovery. As an open access journal since 2009, Pharmaceuticals promotes the dissemination of cutting-edge research and innovative findings globally, facilitating collaboration and knowledge sharing among scientists. With a robust ranking in Scopus, specifically at Rank #56 in Pharmaceutical Science and Rank #65 in Drug Discovery, the journal serves as a critical platform for advancing the field and supporting future developments in therapeutics and pharmaceuticals. Based in Switzerland, Pharmaceuticals continues to inspire a diverse readership of scholars and healthcare professionals who are dedicated to improving health outcomes through innovative research.

Acta Pharmaceutica Sinica B

Advancing the Frontiers of Pharmaceutical Science
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

Drug Metabolism and Pharmacokinetics

Illuminating the Dynamics of Drug Action and Disposition
Publisher: JAPANESE SOC STUDY XENOBIOTICSISSN: 1347-4367Frequency: 6 issues/year

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

TRENDS IN PHARMACOLOGICAL SCIENCES

Shaping the Landscape of Pharmacological Sciences
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.